BASILEA PHARMACEU earnings per share and revenue

PK5 earnings per share for the last semiannual are 1.61 CHF whereas the estimation was 1.17 CHF which accounts for 37.61% surprise. Company revenue for the same period amounts to 76.30 M CHF despite the estimated figure of 106.10 M CHF. Estimated earnings per share for the next semiannual are 2.48 CHF, and revenue is expected to reach 125.93 M CHF. Also watch annual changes over time to get a bigger picture of PK5 earnings per share and revenue dynamics.